Ureteral Stents Market - Global Outlook and Forecast 2021-2026

The growing incidence of several ureteric obstructions associated with kidney stones, kidney transplantation, and tumors is attributing to the global ureteral stent market growth. The rising awareness among the patient population regarding the advanced treatment modalities for ureteric obstructions along with the increasing availability of several effective ureteral stent devices is contributing to the market growth.

According to Arizton, the rising adoption of percutaneous surgery will continue to influence the growth of the global ureteral stents market. The increasing adoption of percutaneous surgery procedure as a lesser risky procedure for diagnosis & treatment with ureteric stents is projected to drive the market growth of the global ureteral stents. In addition, the increasing uptake of Percuflex material with its improved biocompatibility & bio durability is likely to drive significant product innovations, thereby positively influencing the market growth.

Global Ureteral Stents Market: Key Highlights

• The increasing preference for ureteral stents surgery with advanced digital imaging techniques such as X-ray and fluoroscopy is a major factor in the global market.
• The growing focus on metallic stents presents other driving factors for the global ureteral stent market.
• The development of antimicrobial coated ureteric stents with improved safety and efficacy is likely to contribute to the market growth during the forecast period.
• The double pigtail segment is projected to witness an incremental growth of $55 million by 2025 due to the high efficiency of double pigtail stent to prevent the urinary tract's obstruction.
• The kidney stones segment is likely to experience an incremental growth of $31 million by 2025 due to the growing prevalence of kidney stones in the population, especially the elderly.

Global Ureteral Stents Market Segmentation

The double pigtail segment will retain its market dominance during the forecast period. The market is likely to grow at a significant rate during the forecast period. Double pigtails, which are also referred to as double J/double pigtail (J) stents, are widely used in endourologic procedures to treat obstruction, pain, and infections for urologic procedures. Hence, the rise in endourologic procedures is expected to augur well for the segment. The multiloop segment is growing at a faster rate. The report also provides market size and share analysis of the single pigtail and multiloop pigtail stent market.

The kidney stones segment will contribute a major chunk of revenue share to the global ureteral stent market. The kidney stones not only will occupy the largest ureteral stent market share but also is forecasted to grow at the fastest CAGR. The high prevalence of nephrolithiasis (kidney stones) in the elderly population is a major driver for the segment's growth. Nephrolithiasis has been associated with several comorbidities, including hypertension, diabetes mellitus, and metabolic syndrome (MeS). Therefore, a large patient pool and effective treatment of kidney stones are likely to aid in the segment's growth. Furthermore, key players focus on offering innovative ureteral stent materials for treating kidney stones, which effectively treat the disease. The report includes a detailed study of the other application segments: kidney transplantation, tumors, and others.

The polymer segment accounted for more than 85% of the global ureteral stent market share in 2020. The polymer segment is anticipated to retain its market dominance during the forecast period. The meta segment is expected to witness a healthy CAGR during the forecast period. Due to the property of resistance to deformation, metallic ureteral stents are frequently used to treat complicated, malignant obstructions of the ureter and urinary diseases that are difficult to be treated by using conventional treatment methods or polymeric ureteral stents.

The hospital end-user segment accounted for a 50% share of the ureteral stents market. The segment is growing at a healthy rate due to the high adoption of the latest generation devices. Compared to hospitals, urologic clinics offers sophisticated infrastructure related to the diagnosis and treatment of a broad spectrum of urological disorders, including several ureteral obstructions. According to Arizton, the segment is the fast-growing end-user segment.

Insights By Geography

North America ureteral stent market to remain in a dominant position globally. The market is mainly driven by high awareness of kidney-related ailments, a large pool of the patient population, technological advances and better products, and extensive reach of innovative products. The North American region is expected to witness lucrative growth during the forecast period due to the rising technological advancements that influence the higher uptake of easy-to-use medical devices, including ureteric stents. Percutaneous surgery with ureteric stents with improved biocompatible stents is gaining popularity in the European region, thereby driving the uptake of ureteral stents in the region.

The report also includes the ureteral stent market size of the following countries.

• US
• Canada
• UK
• Germany
• France
• Italy
• Spain
• China
• Japan
• South Korea
• Australia
• India
• Brazil
• Mexico
• Argentina
• Saudi Arabia
• South Africa
• Turkey

Competitive Landscape

The global ureteral stents market is highly competitive with the presence of global, regional, and local players offering a broad range of conventional and latest-generation devices. Boston Scientific, BD, Cook Medical, B. Braun Melsungen, and Coloplast are the key vendors in the market. These vendors have high expertise and reach in stent technology, material features, marketing strategies, and distribution channels. These companies have a wide geographic footprint, a diversified product portfolio, and a strong focus on product innovation, R&D, and business expansion activities. Key players are likely to drive sales and margin growth in their business by expanding sales organization, securing additional contracts with commercial payors, maintaining technology leadership through R&D, and continuing to build clinical evidence to support the benefit of new products as well as services.